PMID- 30558294
OWN - NLM
STAT- MEDLINE
DCOM- 20190305
LR  - 20240109
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 23
IP  - 12
DP  - 2018 Dec 15
TI  - Looking at Marine-Derived Bioactive Molecules as Upcoming Anti-Diabetic Agents: A 
      Special Emphasis on PTP1B Inhibitors.
LID - 10.3390/molecules23123334 [doi]
LID - 3334
AB  - Diabetes mellitus (DM) is a chronic metabolic disease with high morbimortality 
      rates. DM has two types: type 1, which is often associated with a total 
      destruction of pancreatic beta cells, and non-insulin-dependent or type 2 
      diabetes mellitus (T2DM), more closely associated with obesity and old age. The 
      main causes of T2DM are insulin resistance and/or inadequate insulin secretion. 
      Protein-tyrosine phosphatase 1B (PTP1B) negatively regulates insulin signaling 
      pathways and plays an important role in T2DM, as its overexpression may induce 
      insulin resistance. Thus, since PTP1B may be a therapeutic target for both T2DM 
      and obesity, the search for novel and promising natural inhibitors has gained 
      much attention. Hence, several marine organisms, including macro and microalgae, 
      sponges, marine invertebrates, sea urchins, seaweeds, soft corals, lichens, and 
      sea grasses, have been recently evaluated as potential drug sources. This review 
      provides an overview of the role of PTP1B in T2DM insulin signaling and 
      treatment, and highlights the recent findings of several compounds and extracts 
      derived from marine organisms and their relevance as upcoming PTP1B inhibitors. 
      In this systematic literature review, more than 60 marine-derived metabolites 
      exhibiting PTP1B inhibitory activity are listed. Their chemical classes, 
      structural features, relative PTP1B inhibitory potency (assessed by IC(50) 
      values), and structure(-)activity relationships (SARs) that could be drawn from the 
      available data are discussed. The upcoming challenge in the field of marine 
      research-metabolomics-is also addressed.
FAU - Ezzat, Shahira M
AU  - Ezzat SM
AD  - Pharmacognosy Department, Faculty of Pharmacy, Cairo University, Kasr El-Ainy 
      Street, Cairo 11562, Egypt. shahira.ezzat@pharma.cu.edu.eg.
AD  - Department of Pharmacognosy, Faculty of Pharmacy, October University for Modern 
      Science and Arts (MSA), Cairo 12566, Egypt. shahira.ezzat@pharma.cu.edu.eg.
FAU - Bishbishy, Mahitab H El
AU  - Bishbishy MHE
AUID- ORCID: 0000-0002-0755-7229
AD  - Department of Pharmacognosy, Faculty of Pharmacy, October University for Modern 
      Science and Arts (MSA), Cairo 12566, Egypt. mahelmy@msa.eun.eg.
FAU - Habtemariam, Solomon
AU  - Habtemariam S
AD  - Herbal Analysis Services UK & Pharmacognosy Research Laboratories, University of 
      Greenwich, Central Avenue, Chatham-Maritime, Kent ME4 4TB, UK. 
      s.habtemariam@gre.ac.uk.
FAU - Salehi, Bahare
AU  - Salehi B
AUID- ORCID: 0000-0002-6900-9797
AD  - Student Research Committee, Bam University of Medical Sciences, Bam 44340847, 
      Iran. bahar.salehi007@gmail.com.
FAU - Sharifi-Rad, Mehdi
AU  - Sharifi-Rad M
AD  - Department of Medical Parasitology, Zabol University of Medical Sciences, Zabol 
      61663-335, Iran. m.sharifirad@zbmu.ac.ir.
FAU - Martins, Natalia
AU  - Martins N
AUID- ORCID: 0000-0002-5934-5201
AD  - Institute for Research and Innovation in Health (i3S), University of Porto, 
      4200-135 Porto, Portugal. ncmartins@med.up.pt.
AD  - Faculty of Medicine, University of Porto, Alameda Prof. Hernani Monteiro, 
      4200-319 Porto, Portugal. ncmartins@med.up.pt.
FAU - Sharifi-Rad, Javad
AU  - Sharifi-Rad J
AUID- ORCID: 0000-0002-7301-8151
AD  - Zabol Medicinal Plants Research Center, Zabol University of Medical Sciences, 
      Zabol 61615-585, Iran. javad.sharifirad@gmail.com.
AD  - Department of Chemistry, Richardson College for the Environmental Science 
      Complex, The University of Winnipeg, 599 Portage Avenue, Winnipeg, MB R3B 2G3, 
      Canada. javad.sharifirad@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20181215
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - EC 3.1.3.48 (Protein Tyrosine Phosphatase, Non-Receptor Type 1)
SB  - IM
MH  - Animals
MH  - *Ecosystem
MH  - Enzyme Inhibitors/chemistry/isolation & purification/*pharmacology
MH  - Humans
MH  - Hypoglycemic Agents/*pharmacology
MH  - Protein Tyrosine Phosphatase, Non-Receptor Type 1/*antagonists & 
      inhibitors/metabolism
PMC - PMC6321226
OTO - NOTNLM
OT  - insulin signaling pathways
OT  - marine metabolites
OT  - protein-tyrosine phosphatase 1B
OT  - type 2 diabetes mellitus
COIS- The authors declare no conflict of interest.
EDAT- 2018/12/19 06:00
MHDA- 2019/03/06 06:00
PMCR- 2018/12/15
CRDT- 2018/12/19 06:00
PHST- 2018/11/30 00:00 [received]
PHST- 2018/12/10 00:00 [revised]
PHST- 2018/12/13 00:00 [accepted]
PHST- 2018/12/19 06:00 [entrez]
PHST- 2018/12/19 06:00 [pubmed]
PHST- 2019/03/06 06:00 [medline]
PHST- 2018/12/15 00:00 [pmc-release]
AID - molecules23123334 [pii]
AID - molecules-23-03334 [pii]
AID - 10.3390/molecules23123334 [doi]
PST - epublish
SO  - Molecules. 2018 Dec 15;23(12):3334. doi: 10.3390/molecules23123334.